Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients.
Tirzepatide just set itself apart from standard GLP-1 agonists in spinal fusion research. A new study from Stony Brook University tracked almost a thousand obese patients who had spinal fusion surgery. The researchers compared those prescribed tirzepatide before surgery with those using older GLP-1 single receptor agonists. The results were clear: tirzepatide delivered better outcomes, both early and long-term.
Eur Spine J
by Sacks GI, Meydan Y, Lebens R et al.
“Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients. Sacks GI(1), Meydan Y(2), Lebens R(2), Mushlin HM(3). Author information: (1)Renaissance School of Medicine, Stony Brook University, Stony Brook, USA. gregory.sacks@stonybrookmedicine.edu. (2)Renaissance School of Medicine, Stony Brook University, Stony Brook, USA. (3)Department of Neurological Surgery, Stony Brook University Hospital, Stony Brook, USA. harry.mushlin@stonybrookmedicine.edu. STUDY DESIGN: Retrospective, propensity score-matched cohort study. PURPOSE: To determine if outcomes following spinal fusion differ between obese patients prescribed Tirzepatide and single receptor glucagon-like-peptide-1 (srGLP-1) agonists preoperatively. METHODS: Data was collected from the TriNetX Research Network. Obese patients undergoing spinal fusion that were prescribed tirzepatide alone in the 6 months preceding surgery, were matched 1:1 based on demographics, comorbidities, medication use, and surgical procedure with those prescribed an srGLP-1 agonist alone in the year prior to surgery. Early (90-day) outcomes included UTI, thrombotic or embolic events, and AKI. Long-term outcomes (2 years) include revision, pseudarthrosis, and post-laminectomy syndrome. RESULTS: A total of 918 matched pairs were analyzed. At 90-days after surgery, tirzepatide patients experienced fewer embolic or thrombotic events (RR 0.41, 95% CI 0.22-0.76, p = 0.003), lower UTI rates (RR 0.47, 95% CI 0.32-0.69, p < 0.001) and less AKIs (RR 0.42, 95% CI 0.26-0.69, p < 0.001) compared to srGLP-1 patients. At 2 years after surgery tirzepatide users had fewer instances of revision (RR 0.65, 95% CI 0.49-0.87, p = 0.003), pseudarthrosis (RR 0.41, 95% CI 0.25-0.68, p < 0.001), post-laminectomy syndrome (RR 0.58, 95% CI 0.31-0.68, p < 0.001) compared to srGLP-1 users. CONCLUSIONS: In a propensity-matched analysis, obese spinal fusion patients treated with Tirzepatide compared to srGLP-1 agonists, had lower rates of early postoperative thrombotic and embolic events, UTIS, and AKIs. Additionally, the Tirzepatide fusion cohort had significantly lower rates of pseudarthrosis, revision surgery, and post-laminectomy syndrome 2 years after surgery. These findings support the potential protective physiological impact of Tirzepatide over srGLP-1s in obese patients undergoing spinal fusion. © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.”
Here’s what stood out:
In the first 90 days after surgery, tirzepatide users had less than half the risk of blood clots or embolic events compared to the GLP-1 group (risk ratio 0.41).
Urinary tract infections dropped by over 50% (risk ratio 0.47).
Acute kidney injury rates were slashed too (risk ratio 0.42).
But it didn’t stop there. Two years later, patients who’d used tirzepatide before surgery still came out ahead:
Revision surgeries were less common (risk ratio 0.65).
Pseudarthrosis—when the bone fusion doesn’t take—was less than half as frequent (risk ratio 0.41).
Post-laminectomy syndrome, a nagging pain complication, also dropped (risk ratio 0.58).
Key takeaway: Tirzepatide appears to offer protective physiological benefits that older GLP-1 agonists can’t match, at least in this surgical context. These numbers make the case for more research into how this peptide influences recovery and tissue healing—especially in challenging patient populations.
The study design was robust, using propensity-matched cohorts and real-world data. If you’re interested in sourcing compounds for similar research or want to see who’s offering tirzepatide, check the vendor directory for more options.
Tirzepatide isn’t just a headline grabber—it’s shaping up as a serious contender for advanced research in metabolic and surgical recovery contexts.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.